A study of three drugs for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three medicines (SYS6002, JMT101, and Enlonstobart) for people with head and neck cancer that has come back or spread and cannot be removed by surgery or radiation. The goal is to see if this treatment helps shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have head and neck cancer that has come back or spread and cannot be cured with local treatments.
- Your cancer started in the mouth, throat (oropharynx or hypopharynx), or voice box (larynx).
- You can provide a sample of your tumor tissue (either a stored one or a fresh biopsy).
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are in fairly good health (able to do daily activities with little help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
This trial tests a new drug called SYS6010 against standard single-drug options in people with head and neck cancer that has returned or spread after prior treatment. The goal is to see if SYS6010 can shrink tumors or slow the disease better than the usual choices.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.